Have you heard about the signing of the Consolidated Appropriations Act of 2023?
With this Act, Congress eliminated the DATA-Waiver Program. This means:
• A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
• There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
• All prescriptions for buprenorphine only require a standard DEA registration number.
